Inhibikase Therapeutics, Inc. Quarterly Costs and Expenses in USD from Q1 2020 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Total costs of sales and operating expenses for the period.
Summary
Inhibikase Therapeutics, Inc. quarterly/annual Costs and Expenses history and growth rate from Q1 2020 to Q3 2024.
  • Inhibikase Therapeutics, Inc. Costs and Expenses for the quarter ending September 30, 2024 was $5.83M, a 20.2% increase year-over-year.
  • Inhibikase Therapeutics, Inc. Costs and Expenses for the twelve months ending September 30, 2024 was $20.1M, a 1.38% decline year-over-year.
  • Inhibikase Therapeutics, Inc. annual Costs and Expenses for 2023 was $20.4M, a 11.5% increase from 2022.
  • Inhibikase Therapeutics, Inc. annual Costs and Expenses for 2022 was $18.3M, a 2.16% increase from 2021.
  • Inhibikase Therapeutics, Inc. annual Costs and Expenses for 2021 was $17.9M, a 408% increase from 2020.
Costs and Expenses, Trailing 12 Months (USD)
Costs and Expenses, Quarterly (USD)
Costs and Expenses, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $20.1M $5.83M +$979K +20.2% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 $19.1M $5.05M -$1.27M -20.1% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 $20.4M $4.78M +$2.89K +0.06% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 $20.4M $4.4M +$5.03K +0.11% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-27
Q3 2023 $20.3M $4.85M +$328K +7.26% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-14
Q2 2023 $20M $6.32M +$1.67M +36% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-14
Q1 2023 $18.3M $4.78M +$92.8K +1.98% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 $18.3M $4.4M -$645K -12.8% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-27
Q3 2022 $18.9M $4.52M -$279K -5.82% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 $19.2M $4.65M +$655K +16.4% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 $18.5M $4.69M +$654K +16.2% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 $17.9M $5.04M +$3.67M +268% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-31
Q3 2021 $14.2M $4.8M +$4.1M +584% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 $10.1M $3.99M +$3.36M +530% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-12
Q1 2021 $6.74M $4.03M +$3.22M +397% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q4 2020 $3.52M $1.37M Oct 1, 2020 Dec 31, 2020 10-K 2022-03-31
Q3 2020 $701K Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 $634K Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-16
Q1 2020 $811K Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-17
* An asterisk sign (*) next to the value indicates that the value is likely invalid.